Bioequivalence study of fluticasone propionate nebuliser suspensions in healthy Chinese subjects.

Journal: Frontiers in pharmacology
Published Date: Jan 3, 2025

Abstract

BACKGROUND: Fluticasone propionate is a synthetic trifluoro-substituted glucocorticoid, a highly selective glucocorticoid receptor agonist. Fluticasone propionate nebuliser suspensions is an inhaled corticosteroid with the low systemic bioavailability which provides a low risk (benefit outcome without the adverse effects that accompany systemically administered corticosteroids), referred as a first-line preventive agent for patients with persistent asthma. China has become one of the countries with the highest asthma mortality rate in the world in the past years. It urgently needs good generic drugs to help ease patients' burden and improve their quality of life.

Authors

  • Feng Cheng
    Phase I Clinical Trial Site, Nanjing Gaoxin Hospital, Nanjing, Jiangsu, China.
  • Tao Shen
    Shanghai Chenpon Pharmaceutical Co., Ltd., Shanghai, China.
  • Fucheng Zhang
    Research Center for Agricultural Monitoring and Early Warning, Agricultural Information Institute of Chinese Academy of Agricultural Sciences, Beijing, China.
  • Chenghao Lei
    Phase I Clinical Trial Site, Nanjing Gaoxin Hospital, Nanjing, Jiangsu, China.
  • Ye Zhu
    Phase I Clinical Trial Site, Nanjing Gaoxin Hospital, Nanjing, Jiangsu, China.
  • GuoJun Luo
    Shanghai Chenpon Pharmaceutical Co., Ltd., Shanghai, China.
  • Dawei Xiao
    Phase I Clinical Trial Site, Nanjing Gaoxin Hospital, Nanjing, Jiangsu, China.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals